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Insomnia
? Common
? Quality of life, work
? Treatment
Dyas JV et al. Patients’ and clinicians’ experiences of consultations in primary care for 
sleep problems and insomnia: a focus group study. BJGP 2010; 60: 329 -333.
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Practitioner beliefs and behaviours
Benzodiazepine
‘Z’ drug
Brief psychotherapy
Anxiety advice sheets
GP verbal advice
Sleep hygiene advice sheets
Sleep restriction
Sedative antihistamines
Phenothiazines
Sedative antidepressant
Non-sedative antidepressant
Referral to counsellor
Referral to CPN
Other referral 
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Insomnia preference 
ranking (1, highest-9, 
lowest) 
Siriwardena AN et al. General practitioners’ preferences for managing insomnia 
and opportunities for reducing hypnotic prescribing. J Eval Clin Pract 2010;16: 
731–737.
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Drugs for sleep
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p re s c rip tio ns
Siriwardena AN et al.  Magic bullets for insomnia? Patients’ use and 
experience of newer (z drugs) versus older benzodiazepine) hypnotics 
for sleep problems in primary care. Br J Gen Pract 2008; 58: 417-22
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Food and Drugs Administration
? Data on approved drugs
? Data on all currently approved (non-
benzodiazepine) Z-drugs: eszopiclone, 
zaleplon and zolpidem from the FDA website
? Quality rating
? PRISMA guidelines
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Study flow
Results
? 13 studies
? 65 drug-placebo comparisons (k) by outcome, 
drug and dosage
? 3985 subjects
? Different countries, treatment lengths, year of 
study
Sleep latency: weighted 
standardized mean differences
Between Group
Weighted mean 
d+ (95% CI)
Within Group 
Weighted mean 
d+ (95% CI)
Primary 
outcomes
-0.33 
(-0.62 to -0.041) 
-0.33 
(-0.63 to -0.033) 
-0.67 
(-1.30 to -0.034) 
4Sleep 
latency 
subjective 
-0.36 
(-0.57 to -0.16) 
-0.39 
(-0.54 to -0.23) 
-0.93 
(-1.32 to -0.54) 
16Sleep 
latency 
PSG 
Experimental 
vs. Control
ControlExperimentalk
Sleep latency (PSG)
www.lincoln.ac.uk
Experimental versus 
control group effect 
sizes of sleep latency
PSG ordered by 
magnitude
NOTE: Weights are from random effects analysis
Overall  (I-squared = 40.6%, p = 0.026)
LSH17 (10 mg)
EFC4529
Trial 306 (10 mg)
190-047
Trial 303 (Zaleplon 10 mg)
204-EU (20 mg)
Trial 301 (Zaleplon 10 mg)
EC4530
Trial 307 (Zaleplon 10/20 mg)
204-EU (Zaleplon 10 mg)
Trial 307 (Zaleplon 10/10 mg)
IV LSHI (15 mg)
204-EU (Zolpidem 10 mg)
IV LSHI (10 mg)
LSH17 (15 mg)
Trial 303 (Zaleplon 5 mg)
ID
Trial 303 (Zaleplon 20 mg)
Trial 301 (Zolpidem 10 mg)
Trial 301 (Zaleplon 20 mg)
Trial 306 (5 mg)
Trial 301 (Zaleplon 5 mg)
Study
Trial 303 (Zolpidem 10 mg)
-0.36 (-0.45, -0.28)
-0.69 (-1.29, -0.09)
-0.22 (-0.50, 0.06)
-0.40 (-0.64, -0.17)
-0.50 (-0.75, -0.25)
-0.31 (-0.59, -0.04)
-0.03 (-0.53, 0.46)
-0.54 (-0.80, -0.27)
-0.29 (-0.59, 0.02)
-0.29 (-0.50, -0.08)
-0.18 (-0.67, 0.31)
-0.24 (-0.45, -0.03)
-0.56 (-1.13, 0.01)
-0.14 (-0.62, 0.34)
-0.30 (-0.85, 0.26)
-0.69 (-1.29, -0.09)
-0.17 (-0.45, 0.10)
ES (95% CI)
-0.39 (-0.67, -0.11)
-0.62 (-0.88, -0.36)
-0.80 (-1.07, -0.54)
-0.41 (-0.66, -0.17)
-0.01 (-0.27, 0.24)
-0.31 (-0.59, -0.04)
Favors Experimental  Favors Control 
0-1.50 -1.25 -1 -0.75 -0.50 -0.25 0.25 0.50
Sleep latency: weighted raw mean 
differences
Between Group
Weighted mean 
d+ (95% CI)
Within Group 
Weighted mean 
d+ (95% CI)
Primary 
outcomes
-6.9
(-26.0 to + 12.4) 
-19.4
(-26.6 to -12.2) 
-25
(-30.1 to -19.9) 
2Sleep 
latency 
subjective 
-22.0 
(-33.0 to -11.0) 
-20
(-28.0 to -11.0) 
-42
(-60.0 to -23.0)
14Sleep 
latency 
PSG 
Experimental 
vs. Control
ControlExperimentalk
Homogeneity of effect sizes
Homogeneity of effect sizes  I2 (95% CI)Primary 
outcomes
83 
(70.98 to 90.05) 
0 
(0 to 66.15) 
0 
(0 to 49.26) 
4Sleep 
latency 
subjective 
41 
(1.18 to 64.30) 
0 
(0 to 77.60) 
89 
(83.58 to 92.47) 
16Sleep 
latency 
PSG 
Experimental 
vs. Control
ControlExperimentalk
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Moderator analysis
Conclusions
? Z-drugs have limited benefit
? Small reductions in subjective and PSG sleep 
latency especially with larger dosages
? No improvement in other sleep measures compared 
to placebo. 
? Placebo effects were moderate for sleep latency.
? Hypnotics are more effective in women, younger 
patients, larger drugs doses and older studies
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Contact: nsiriwardena@lincoln.ac.uk
Web:  http://www.cahru.org.uk/
REST website: http://www.restproject.org.uk/
REST E-learning: http://elearning.restproject.org.uk/
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